secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2026-05-27T20:18:04+00:00
Accession:  0001193125-26-241930
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks
--------------------------------------------------------------------------------

- Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.
- Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.
- Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.
- No obligation to sell any shares; program provides capital-raising flexibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/0001193125-26-241930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-241930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer